Loading
In a single-arm study of 53 people with MYC-rearranged aggressive B-cell lymphoma, including double-hit disease, intensive infusional chemotherapy left 71 per cent alive and free of events at four years.
The final analysis of a prospective multicentre single-arm phase 2 study (NCT01092182) of dose-adjusted EPOCH-R, given with CNS prophylaxis for six cycles, in untreated aggressive B-cell lymphoma with MYC rearrangement. Primary endpoints included event-free and overall survival. The background the authors give: MYC rearrangement is present in about 10 per cent of aggressive B-cell lymphomas, half of which also carry a BCL2 rearrangement.
Prospective, single-arm evidence for treating MYC-rearranged and double-hit large B-cell lymphoma more intensively than with R-CHOP. It has no control arm, which the entity page says plainly: there has never been a randomised trial confined to this group.
Shares Prednisone, Vincristine, Etoposide, Doxorubicin and the tag lymphoma-evidence-entities.
Shares Etoposide and the tag lymphoma-evidence-entities.
Shares Etoposide and the tag lymphoma-evidence-entities.
Shares Etoposide and the tag lymphoma-evidence-entities.
Shares Double-hit / high-grade B-cell lymphoma, Alliance/CALGB 50303, Prednisone, Vincristine.
Shares Prednisone, Vincristine, Rituximab, Doxorubicin.
Shares Prednisone, Vincristine, Rituximab, Doxorubicin.
Shares Prednisone, Vincristine, Rituximab, Doxorubicin.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/